Related Experiment Video
Updated: Sep 27, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible
Vincenzo Di Marzo1, Tiziana Bisogno, Luciano De Petrocellis
1Istituto per la Chimica di Molecole di Interesse Biologico, Via Toiano 6, 80072, Arco Felice (NA), Italy.
Abstract:
Changes in the levels of either the cannabinoid CB(1) receptors or of their endogenous ligands, anandamide and 2-arachidonoylglycerol, appear to be casual or consequential in many neurological disorders. Several examples of how such diseases may be treated by substances capable of selectively manipulating endocannabinoid levels and action are presented, using animal models of neuropathological conditions, such as motor disorders, multiple sclerosis, neuronal damage, chronic and inflammatory pain, anorexia, cachexia and motivational disturbances. These examples indicate that new therapeutic agents, lacking the undesirable psychotropic side effects of Cannabis, may be developed from current studies on the endocannabinoid system.
Related Concept Videos
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
CNS Stimulants: Psychedelic Agents
Analgesia and Pain Management
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Cerebral Edema ll: Pathophysiology
